GMP Update: Reducing Obstacles to Innovation

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-10-02-2003, Volume 27, Issue 10

FDA offers new policies to encourage modern manufacturing approaches and automated systems, to simplify postapproval changes, and to avoid problems with sterile products.

Related Content:

Regulatory/GMP ComplianceRegulatory WatchPharmaceutical Technology-10-02-2003
Susan Schniepp of Regulatory Compliance Associates Explores the Impact of QMS on Quality Maturity (INTERPHEX 2024)
Keynote Session Highlights Importance of Process Validation and Data Integrity (INTERPHEX 2024)
FDA Establishes Center for Clinical Trial Innovation